At the same level of stringency, fewer than 500 sites exhibited differential FOXA1 binding between these categories; by comparison, FOXA1 binding was gained at 20,935 and lost at 29,308 sites in NEPC compared to metastatic PRAD (Fig. 3d). This evidence concerns the gene FOXA1 and prostate adenocarcinoma.